Quest Diagnostics Inc
DGXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Quest Diagnostics Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 19 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 8, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| MONTGOMERY INVESTMENT MANAGEMENT INC | 2026-03-31 | 4,219 | $827K | SEC filing |
| ELEVATION WEALTH PARTNERS, LLC | 2026-03-31 | 34 | $6.66K | SEC filing |
| BALLAST ADVISORS LLC | 2026-03-31 | 100 | Not shown | SEC filing |
| M.D. Sass, LLC | 2026-03-31 | 299,459 | $58.7M | SEC filing |
| Costello Asset Management, INC | 2026-03-31 | 100 | $19.6K | SEC filing |
| APPLETON PARTNERS INC/MA | 2026-03-31 | 21,125 | Not shown | SEC filing |
| Allegheny Financial Group | 2026-03-31 | 1,597 | $313K | SEC filing |
| Dorsey & Whitney Trust CO LLC | 2026-03-31 | 1,718 | $337K | SEC filing |
| PEAPACK GLADSTONE FINANCIAL CORP | 2026-03-31 | 10,945 | Not shown | SEC filing |
| Park Square Financial Group, LLC | 2026-03-31 | 35 | $6.86K | SEC filing |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 2026-03-31 | 295,035 | $58.2M | SEC filing |
| Baker Avenue Asset Management, LP | 2026-03-31 | 1,442 | $283K | SEC filing |
| WATERS PARKERSON & CO., LLC | 2026-03-31 | 2,350 | $461K | SEC filing |
| PARK NATIONAL CORP /OH/ | 2026-03-31 | 479 | $93.9K | SEC filing |
| COOKSON PEIRCE & CO INC | 2026-03-31 | 156,342 | $30.6M | SEC filing |
| SEB Asset Management AB | 2026-03-31 | 139,951 | $27.4M | SEC filing |
| BENJAMIN EDWARDS INC | 2026-03-31 | 8,204 | $1.61M | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 5,746 | $1.13M | SEC filing |
| Merkkuri Wealth Advisors LLC | 2026-03-31 | 108 | $21.1K | SEC filing |
| Johnson Financial Group, Inc. | 2026-03-31 | 95 | $18.6K | SEC filing |
- Each value is checked against Quest Diagnostics Inc's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 3 rows: the filed value is about 1,000 times too small for the share count at Quest Diagnostics Inc's share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Quest Diagnostics Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-06-01 · Davis J. E.: Larger than 59 of the 64 other insider sales of Common Stock on file. SEC filing
- 2026-03-02 · Davis J. E.: Larger than 59 of the 64 other insider sales of Common Stock on file. SEC filing
- 2026-02-13 · Doherty Catherine T.: Larger than 62 of the 64 other insider sales of Common Stock on file. SEC filing
- 2026-02-13 · Doherty Catherine T.: Larger than 61 of the 64 other insider sales of Common Stock on file. SEC filing
- 2025-11-25 · Davis J. E.: Larger than 58 of the 64 other insider sales of Common Stock on file. SEC filing
- 2025-11-25 · Davis J. E.: Larger than all 64 other insider sales of Common Stock on file. SEC filing
- 2025-09-23 · PREVOZNIK MICHAEL E: Larger than 63 of the 64 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-04 | KUPPUSAMY KARTHIK · SVP, Clinical Solutions | Common Stock | S — Open market or private sale | −8,147 | 200.00 | SEC filing |
| 2026-06-01 | Davis J. E. · CEO and President | Common Stock | S — Open market or private sale | −10,000 | 194.14 | SEC filing |
| 2026-03-05 | PREVOZNIK MICHAEL E · SVP & General Counsel | Common Stock | S — Open market or private sale | −3,878 | 206.21 | SEC filing |
| 2026-03-05 | Plewman Patrick · SVP for Diagnostic Services | Common Stock | S — Open market or private sale | −2,855 | 206.21 | SEC filing |
| 2026-03-05 | Doherty Catherine T. · EVP, Regional Businesses | Common Stock | S — Open market or private sale | −5,558 | 206.21 | SEC filing |
| 2026-03-04 | KUPPUSAMY KARTHIK · SVP, Clinical Solutions | Common Stock | S — Open market or private sale | −2,628 | 204.86 | SEC filing |
| 2026-03-03 | Plewman Patrick · SVP for Diagnostic Services | Common Stock | S — Open market or private sale | −410 | 207.73 | SEC filing |
| 2026-03-03 | PREVOZNIK MICHAEL E · SVP & General Counsel | Common Stock | S — Open market or private sale | −526 | 207.73 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-04 | KUPPUSAMY KARTHIK · SVP, Clinical Solutions | Common Stock | M — Exercise or conversion of derivative security | +3,320 | SEC filing |
| 2026-06-04 | KUPPUSAMY KARTHIK · SVP, Clinical Solutions | Non-Qualifed Stock Option (right to buy) | M — Exercise or conversion of derivative security | −3,320 | SEC filing |
| 2026-06-04 | KUPPUSAMY KARTHIK · SVP, Clinical Solutions | Common Stock | M — Exercise or conversion of derivative security | +4,827 | SEC filing |
| 2026-06-04 | KUPPUSAMY KARTHIK · SVP, Clinical Solutions | Non-Qualifed Stock Option (right to buy) | M — Exercise or conversion of derivative security | −4,827 | SEC filing |
| 2026-05-20 | CARTER ROBERT B · Director | Common Stock | A — Grant, award, or other acquisition | +1,142 | SEC filing |
| 2026-05-20 | MAIN TIMOTHY L · Director | Common Stock | A — Grant, award, or other acquisition | +1,142 | SEC filing |
| 2026-05-20 | Lassiter Wright III · Director | Common Stock | A — Grant, award, or other acquisition | +1,142 | SEC filing |
| 2026-05-20 | PFEIFFER GARY M · Director | Common Stock | A — Grant, award, or other acquisition | +1,142 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-04-20 | Lassiter Wright III · Director | Common Stock | L — Small acquisition | +6 | SEC filing |
| 2026-04-20 | KUPPUSAMY KARTHIK · SVP, Clinical Solutions | Common Stock | L — Small acquisition | +39 | SEC filing |
| 2026-04-20 | DELANEY MARK E · SVP & Chief Commercial Officer | Common Stock | L — Small acquisition | +37 | SEC filing |
| 2026-04-20 | CARTER ROBERT B · Director | Common Stock | L — Small acquisition | +7 | SEC filing |
| 2026-04-20 | Plewman Patrick · SVP for Diagnostic Services | Common Stock | L — Small acquisition | +49 | SEC filing |
| 2026-01-28 | CARTER ROBERT B · Director | Common Stock | L — Small acquisition | +6 | SEC filing |
| 2026-01-28 | Gregg Vicky B · Director | Common Stock | L — Small acquisition | +67 | SEC filing |
| 2026-01-28 | Lassiter Wright III · Director | Common Stock | L — Small acquisition | +7 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.